Aurobindo Pharma Ltd 2023 IR
The report highlights Aurobindo Pharma Limited's transition to its inaugural Integrated Annual Report for the fiscal year 2022-23. During the year, the company achieved a revenue of INR 24,855 crores and a net profit of INR 1,928 crores. On the sustainability front, the company achieved a 17% reduction in carbon emissions from the baseline year FY20, surpassing its 2025 target. Additionally, it utilized approximately 11.85% of renewable energy in its operations and reused 29% of treated wastewater. The company also made significant progress on its Penicillin-G project under the PLI scheme and advanced its biosimilar pipeline.
Company: Aurobindo Pharma Ltd
Sector: Health Care
Country: India
Year: 2023
Type: IR
Pages: 211
Aurobindo Pharma Ltd
Integrated Annual Report
The report highlights Aurobindo Pharma Limited's transition to its inaugural Integrated Annual Report for the fiscal year 2022-23. During the year, the company achieved a revenue of INR 24,855 crores and a net profit of INR 1,928 crores. On the sustainability front, the company achieved a 17% reduction in carbon emissions from the baseline year FY20, surpassing its 2025 target. Additionally, it utilized approximately 11.85% of renewable energy in its operations and reused 29% of treated wastewater. The company also made significant progress on its Penicillin-G project under the PLI scheme and advanced its biosimilar pipeline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees